左甲状腺素治疗亚临床甲状腺功能减退症与不良心血管事件风险
这项基于英国临床实践研究数据链的队列研究,纳入1998至2018年间至少有两次促甲状腺激素(TSH)在5至10 mU/L的成人亚临床甲状腺功能减退症(SCH)患者,匹配76,946例左甲状腺素治疗者与76,946例未治疗者。作者指出鉴于研究的观察性性质,解释该发现时应考虑残余混杂。
要点
- 治疗组MACE发生率为12.8/1000人年,未治疗组为13.9/1000人年。
- 研究为观察性设计,解释结果时应考虑残余混杂。
核心结论
- 左甲状腺素治疗SCH与MACE风险小幅降低相关,但鉴于研究的观察性性质,解释该发现时应考虑残余混杂。
研究设计与样本
- 采用基于人群的队列研究,使用流行新用户设计,数据来自英国临床实践研究数据链。
- 基础队列为1998至2018年间18岁及以上、一年内至少两次TSH在5至10 mU/L的偶发SCH个体。
- 按年龄、性别、日历时间、SCH病程和时间条件倾向评分,匹配76,946例左甲状腺素治疗者与76,946例未治疗者。
主要发现
- 研究队列平均年龄62.8岁,女性占76.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究为观察性性质,解释结果时应考虑残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Importance: There is uncertainty as to whether treatment of subclinical hypothyroidism (SCH) is associated with cardiovascular outcomes. Objectives: To determine whether levothyroxine replacement therapy decreases the risk of major adverse cardiovascular events (MACE) among individuals with SCH defined as having a thyrotropin (TSH) level between 5 and 10 mU/L. Design: We conducted a population-based cohort study using a prevalent new-user design. Setting: The study utilized data from the United Kingdom Clinical Practice Research Datalink. Participants: We identified a base cohort of individuals aged ≥18 years with incident SCH defined as having at least two TSH levels between 5 and 10 mU/L within one year between 1998 and 2018. We matched 76,946 levothyroxine treated to 76,946 untreated individuals based on age, sex, calendar time, duration of SCH, and time-conditional propensity score. We compared individuals with SCH treated with levothyroxine with individuals with no treatment. Exposure: Levothyroxine treatment versus no treatment. Main Outcome Measures: The primary outcome, MACE, was defined as a composite of nonfatal myocardial infarction, nonfatal ischemic stroke, and cardiovascular-related mortality. Results: The mean age of the study cohort was 62.8 years, and 76.5% were women. During a median follow-up time of 1.6 years (interquartile range: 0.5-4.2), the incidence rate for MACE among individuals treated with levothyroxine was 12.8 per 1000 person-years; confidence interval (CI): 12.2-13.3 and 13.9 per 1000 person-years; CI: 13.4-14.3 among nontreated individuals. Levothyroxine treatment was associated with a small decreased risk of MACE (hazard ratio: 0.88; CI: 0.83-0.93). Conclusions: Levothyroxine treatment of SCH was associated with a small decreased risk of MACE. However, given the observational nature of the study, residual confounding should be considered in the interpretation of this finding.
引用
- Yu OHY, Filliter C, Filion KB, et al. Levothyroxine Treatment of Subclinical Hypothyroidism and the Risk of Adverse Cardiovascular Events. Thyroid. 2024. PMID: 39104265. doi:10.1089/thy.2024.0227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。